Nasus Pharma Ltd.
Get $10 bonus on your first $100 deposit for NSRX
Get $10 bonus on your first $100 deposit for NSRX
Nasus Pharma Ltd. (NSRX) Stock Competitors & Peer Comparison
See (NSRX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NSRX | $2.20 | -5.17% | 19M | -3.11 | -$0.71 | N/A |
| VRTX | $436.27 | -2.35% | 110.8B | 28.46 | $15.33 | N/A |
| REGN | $748.87 | -2.47% | 77.8B | 18.04 | $41.51 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $799.65 | -0.11% | 49.5B | 40.90 | $19.55 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $322.11 | +0.26% | 42.7B | 138.26 | $2.33 | N/A |
| INSM | $154.81 | -3.00% | 33.4B | -24.13 | -$6.42 | N/A |
| UTHR | $571.73 | -0.53% | 25.1B | 20.54 | $27.84 | N/A |
| BNTX | $95.50 | +3.83% | 24B | -17.62 | -$5.42 | N/A |
Stock Comparison
NSRX vs VRTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, VRTX has a market cap of 110.8B. Regarding current trading prices, NSRX is priced at $2.20, while VRTX trades at $436.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas VRTX's P/E ratio is 28.46. In terms of profitability, NSRX's ROE is +0.00%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, NSRX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check VRTX's competition here
NSRX vs REGN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, REGN has a market cap of 77.8B. Regarding current trading prices, NSRX is priced at $2.20, while REGN trades at $748.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas REGN's P/E ratio is 18.04. In terms of profitability, NSRX's ROE is +0.00%, compared to REGN's ROE of +0.15%. Regarding short-term risk, NSRX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check REGN's competition here
NSRX vs VRNA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, NSRX is priced at $2.20, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas VRNA's P/E ratio is -102.80. In terms of profitability, NSRX's ROE is +0.00%, compared to VRNA's ROE of -0.13%. Regarding short-term risk, NSRX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check VRNA's competition here
NSRX vs ARGX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ARGX has a market cap of 49.5B. Regarding current trading prices, NSRX is priced at $2.20, while ARGX trades at $799.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ARGX's P/E ratio is 40.90. In terms of profitability, NSRX's ROE is +0.00%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, NSRX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ARGX's competition here
NSRX vs SGEN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, NSRX is priced at $2.20, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas SGEN's P/E ratio is -57.19. In terms of profitability, NSRX's ROE is +0.00%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, NSRX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check SGEN's competition here
NSRX vs ALNY Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ALNY has a market cap of 42.7B. Regarding current trading prices, NSRX is priced at $2.20, while ALNY trades at $322.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ALNY's P/E ratio is 138.26. In terms of profitability, NSRX's ROE is +0.00%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, NSRX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ALNY's competition here
NSRX vs INSM Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, INSM has a market cap of 33.4B. Regarding current trading prices, NSRX is priced at $2.20, while INSM trades at $154.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas INSM's P/E ratio is -24.13. In terms of profitability, NSRX's ROE is +0.00%, compared to INSM's ROE of -1.68%. Regarding short-term risk, NSRX is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check INSM's competition here
NSRX vs UTHR Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, UTHR has a market cap of 25.1B. Regarding current trading prices, NSRX is priced at $2.20, while UTHR trades at $571.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas UTHR's P/E ratio is 20.54. In terms of profitability, NSRX's ROE is +0.00%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, NSRX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check UTHR's competition here
NSRX vs BNTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, BNTX has a market cap of 24B. Regarding current trading prices, NSRX is priced at $2.20, while BNTX trades at $95.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas BNTX's P/E ratio is -17.62. In terms of profitability, NSRX's ROE is +0.00%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, NSRX is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check BNTX's competition here
NSRX vs RPRX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RPRX has a market cap of 20.5B. Regarding current trading prices, NSRX is priced at $2.20, while RPRX trades at $47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RPRX's P/E ratio is 26.91. In terms of profitability, NSRX's ROE is +0.00%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, NSRX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RPRX's competition here
NSRX vs BGNE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, NSRX is priced at $2.20, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas BGNE's P/E ratio is -22.55. In terms of profitability, NSRX's ROE is +0.00%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, NSRX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check BGNE's competition here
NSRX vs ROIV Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ROIV has a market cap of 20.2B. Regarding current trading prices, NSRX is priced at $2.20, while ROIV trades at $28.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ROIV's P/E ratio is -24.11. In terms of profitability, NSRX's ROE is +0.00%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, NSRX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ROIV's competition here
NSRX vs MRNA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, MRNA has a market cap of 20.1B. Regarding current trading prices, NSRX is priced at $2.20, while MRNA trades at $50.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas MRNA's P/E ratio is -7.02. In terms of profitability, NSRX's ROE is +0.00%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, NSRX is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check MRNA's competition here
NSRX vs INCY Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, INCY has a market cap of 19.1B. Regarding current trading prices, NSRX is priced at $2.20, while INCY trades at $96.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas INCY's P/E ratio is 14.99. In terms of profitability, NSRX's ROE is +0.00%, compared to INCY's ROE of +0.29%. Regarding short-term risk, NSRX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check INCY's competition here
NSRX vs RVMD Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RVMD has a market cap of 19.1B. Regarding current trading prices, NSRX is priced at $2.20, while RVMD trades at $96.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RVMD's P/E ratio is -16.21. In terms of profitability, NSRX's ROE is +0.00%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, NSRX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RVMD's competition here
NSRX vs DNA-WT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, NSRX is priced at $2.20, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, NSRX is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check DNA-WT's competition here
NSRX vs GMAB Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, GMAB has a market cap of 17.4B. Regarding current trading prices, NSRX is priced at $2.20, while GMAB trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas GMAB's P/E ratio is 18.34. In terms of profitability, NSRX's ROE is +0.00%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, NSRX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check GMAB's competition here
NSRX vs ASND Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, NSRX is priced at $2.20, while ASND trades at $239.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ASND's P/E ratio is -55.13. In terms of profitability, NSRX's ROE is +0.00%, compared to ASND's ROE of +1.28%. Regarding short-term risk, NSRX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ASND's competition here
NSRX vs SMMT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, SMMT has a market cap of 14.6B. Regarding current trading prices, NSRX is priced at $2.20, while SMMT trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas SMMT's P/E ratio is -13.66. In terms of profitability, NSRX's ROE is +0.00%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, NSRX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check SMMT's competition here
NSRX vs BBIO Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, BBIO has a market cap of 14.5B. Regarding current trading prices, NSRX is priced at $2.20, while BBIO trades at $74.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas BBIO's P/E ratio is -19.73. In terms of profitability, NSRX's ROE is +0.00%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, NSRX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check BBIO's competition here
NSRX vs KRTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, NSRX is priced at $2.20, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas KRTX's P/E ratio is -28.09. In terms of profitability, NSRX's ROE is +0.00%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, NSRX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check KRTX's competition here
NSRX vs IONS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, IONS has a market cap of 12.4B. Regarding current trading prices, NSRX is priced at $2.20, while IONS trades at $75.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas IONS's P/E ratio is -31.58. In terms of profitability, NSRX's ROE is +0.00%, compared to IONS's ROE of -0.69%. Regarding short-term risk, NSRX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check IONS's competition here
NSRX vs JAZZ Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, JAZZ has a market cap of 12B. Regarding current trading prices, NSRX is priced at $2.20, while JAZZ trades at $194.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas JAZZ's P/E ratio is -33.25. In terms of profitability, NSRX's ROE is +0.00%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, NSRX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check JAZZ's competition here
NSRX vs MDGL Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, NSRX is priced at $2.20, while MDGL trades at $519.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas MDGL's P/E ratio is -40.37. In terms of profitability, NSRX's ROE is +0.00%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, NSRX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check MDGL's competition here
NSRX vs EXEL Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, NSRX is priced at $2.20, while EXEL trades at $44.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas EXEL's P/E ratio is 15.92. In terms of profitability, NSRX's ROE is +0.00%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, NSRX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check EXEL's competition here
NSRX vs RNAM Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, NSRX is priced at $2.20, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RNAM's P/E ratio is -17.39. In terms of profitability, NSRX's ROE is +0.00%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, NSRX is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RNAM's competition here
NSRX vs BMRN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, BMRN has a market cap of 10.5B. Regarding current trading prices, NSRX is priced at $2.20, while BMRN trades at $54.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas BMRN's P/E ratio is 30.29. In terms of profitability, NSRX's ROE is +0.00%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, NSRX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check BMRN's competition here
NSRX vs RXDX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, NSRX is priced at $2.20, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RXDX's P/E ratio is -56.47. In terms of profitability, NSRX's ROE is +0.00%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, NSRX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RXDX's competition here
NSRX vs ARWR Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ARWR has a market cap of 9.1B. Regarding current trading prices, NSRX is priced at $2.20, while ARWR trades at $65.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ARWR's P/E ratio is 40.71. In terms of profitability, NSRX's ROE is +0.00%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, NSRX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ARWR's competition here
NSRX vs AXSM Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, AXSM has a market cap of 9.1B. Regarding current trading prices, NSRX is priced at $2.20, while AXSM trades at $178.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas AXSM's P/E ratio is -47.12. In terms of profitability, NSRX's ROE is +0.00%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, NSRX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check AXSM's competition here
NSRX vs PCVX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, NSRX is priced at $2.20, while PCVX trades at $60.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas PCVX's P/E ratio is -10.81. In terms of profitability, NSRX's ROE is +0.00%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, NSRX is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check PCVX's competition here
NSRX vs IMGN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, NSRX is priced at $2.20, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas IMGN's P/E ratio is -111.55. In terms of profitability, NSRX's ROE is +0.00%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, NSRX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check IMGN's competition here
NSRX vs TECH Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, TECH has a market cap of 8.7B. Regarding current trading prices, NSRX is priced at $2.20, while TECH trades at $55.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas TECH's P/E ratio is 104.79. In terms of profitability, NSRX's ROE is +0.00%, compared to TECH's ROE of +0.04%. Regarding short-term risk, NSRX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check TECH's competition here
NSRX vs BPMC Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, NSRX is priced at $2.20, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas BPMC's P/E ratio is -51.58. In terms of profitability, NSRX's ROE is +0.00%, compared to BPMC's ROE of -0.15%. Regarding short-term risk, NSRX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check BPMC's competition here
NSRX vs ABVX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ABVX has a market cap of 8.3B. Regarding current trading prices, NSRX is priced at $2.20, while ABVX trades at $126.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ABVX's P/E ratio is -22.25. In terms of profitability, NSRX's ROE is +0.00%, compared to ABVX's ROE of -1.59%. Regarding short-term risk, NSRX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ABVX's competition here
NSRX vs CERE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, NSRX is priced at $2.20, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CERE's P/E ratio is -16.47. In terms of profitability, NSRX's ROE is +0.00%, compared to CERE's ROE of -0.72%. Regarding short-term risk, NSRX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CERE's competition here
NSRX vs CYTK Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CYTK has a market cap of 8B. Regarding current trading prices, NSRX is priced at $2.20, while CYTK trades at $65.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CYTK's P/E ratio is -9.94. In terms of profitability, NSRX's ROE is +0.00%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, NSRX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CYTK's competition here
NSRX vs HALO Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, HALO has a market cap of 8B. Regarding current trading prices, NSRX is priced at $2.20, while HALO trades at $67.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas HALO's P/E ratio is 26.49. In terms of profitability, NSRX's ROE is +0.00%, compared to HALO's ROE of +0.93%. Regarding short-term risk, NSRX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check HALO's competition here
NSRX vs KRYS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, KRYS has a market cap of 7.6B. Regarding current trading prices, NSRX is priced at $2.20, while KRYS trades at $259.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas KRYS's P/E ratio is 37.87. In terms of profitability, NSRX's ROE is +0.00%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, NSRX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check KRYS's competition here
NSRX vs NUVL Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, NUVL has a market cap of 7.5B. Regarding current trading prices, NSRX is priced at $2.20, while NUVL trades at $102.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas NUVL's P/E ratio is -17.62. In terms of profitability, NSRX's ROE is +0.00%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, NSRX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check NUVL's competition here
NSRX vs IBRX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, NSRX is priced at $2.20, while IBRX trades at $7.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas IBRX's P/E ratio is -19.16. In terms of profitability, NSRX's ROE is +0.00%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, NSRX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check IBRX's competition here
NSRX vs MTSR Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, NSRX is priced at $2.20, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas MTSR's P/E ratio is -23.58. In terms of profitability, NSRX's ROE is +0.00%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, NSRX is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check MTSR's competition here
NSRX vs KYMR Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, KYMR has a market cap of 6.9B. Regarding current trading prices, NSRX is priced at $2.20, while KYMR trades at $85.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas KYMR's P/E ratio is -23.05. In terms of profitability, NSRX's ROE is +0.00%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, NSRX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check KYMR's competition here
NSRX vs MRUS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, NSRX is priced at $2.20, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas MRUS's P/E ratio is -17.05. In terms of profitability, NSRX's ROE is +0.00%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, NSRX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check MRUS's competition here
NSRX vs BLTE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, BLTE has a market cap of 6.8B. Regarding current trading prices, NSRX is priced at $2.20, while BLTE trades at $172.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas BLTE's P/E ratio is -74.79. In terms of profitability, NSRX's ROE is +0.00%, compared to BLTE's ROE of -0.23%. Regarding short-term risk, NSRX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check BLTE's competition here
NSRX vs ACLX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, NSRX is priced at $2.20, while ACLX trades at $114.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ACLX's P/E ratio is -28.14. In terms of profitability, NSRX's ROE is +0.00%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, NSRX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ACLX's competition here
NSRX vs PRAX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, PRAX has a market cap of 6.7B. Regarding current trading prices, NSRX is priced at $2.20, while PRAX trades at $316.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas PRAX's P/E ratio is -23.44. In terms of profitability, NSRX's ROE is +0.00%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, NSRX is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check PRAX's competition here
NSRX vs RETA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, NSRX is priced at $2.20, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RETA's P/E ratio is -66.29. In terms of profitability, NSRX's ROE is +0.00%, compared to RETA's ROE of +0.47%. Regarding short-term risk, NSRX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RETA's competition here
NSRX vs PTGX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, PTGX has a market cap of 6.3B. Regarding current trading prices, NSRX is priced at $2.20, while PTGX trades at $98.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas PTGX's P/E ratio is -47.97. In terms of profitability, NSRX's ROE is +0.00%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, NSRX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check PTGX's competition here
NSRX vs COGT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, COGT has a market cap of 5.9B. Regarding current trading prices, NSRX is priced at $2.20, while COGT trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas COGT's P/E ratio is -16.24. In terms of profitability, NSRX's ROE is +0.00%, compared to COGT's ROE of -1.00%. Regarding short-term risk, NSRX is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check COGT's competition here
NSRX vs CNTA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CNTA has a market cap of 5.9B. Regarding current trading prices, NSRX is priced at $2.20, while CNTA trades at $39.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CNTA's P/E ratio is -27.04. In terms of profitability, NSRX's ROE is +0.00%, compared to CNTA's ROE of -0.51%. Regarding short-term risk, NSRX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CNTA's competition here
NSRX vs RYTM Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, NSRX is priced at $2.20, while RYTM trades at $84.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RYTM's P/E ratio is -27.14. In terms of profitability, NSRX's ROE is +0.00%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, NSRX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RYTM's competition here
NSRX vs SRRK Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, NSRX is priced at $2.20, while SRRK trades at $49.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas SRRK's P/E ratio is -15.19. In terms of profitability, NSRX's ROE is +0.00%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, NSRX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check SRRK's competition here
NSRX vs CGON Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CGON has a market cap of 5.7B. Regarding current trading prices, NSRX is priced at $2.20, while CGON trades at $67.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CGON's P/E ratio is -32.55. In terms of profitability, NSRX's ROE is +0.00%, compared to CGON's ROE of -0.23%. Regarding short-term risk, NSRX is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CGON's competition here
NSRX vs PTCT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, PTCT has a market cap of 5.7B. Regarding current trading prices, NSRX is priced at $2.20, while PTCT trades at $68.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas PTCT's P/E ratio is 7.93. In terms of profitability, NSRX's ROE is +0.00%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, NSRX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check PTCT's competition here
NSRX vs CELC Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CELC has a market cap of 5.7B. Regarding current trading prices, NSRX is priced at $2.20, while CELC trades at $117.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CELC's P/E ratio is -30.91. In terms of profitability, NSRX's ROE is +0.00%, compared to CELC's ROE of -2.03%. Regarding short-term risk, NSRX is less volatile compared to CELC. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check CELC's competition here
NSRX vs CDTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, NSRX is priced at $2.20, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CDTX's P/E ratio is -19.77. In terms of profitability, NSRX's ROE is +0.00%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, NSRX is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CDTX's competition here
NSRX vs ALKS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ALKS has a market cap of 5.6B. Regarding current trading prices, NSRX is priced at $2.20, while ALKS trades at $33.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ALKS's P/E ratio is 24.00. In terms of profitability, NSRX's ROE is +0.00%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, NSRX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ALKS's competition here
NSRX vs ABCM Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, NSRX is priced at $2.20, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, NSRX's ROE is +0.00%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, NSRX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ABCM's competition here
NSRX vs ISEE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, NSRX is priced at $2.20, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ISEE's P/E ratio is -22.44. In terms of profitability, NSRX's ROE is +0.00%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, NSRX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ISEE's competition here
NSRX vs TGTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, TGTX has a market cap of 5.4B. Regarding current trading prices, NSRX is priced at $2.20, while TGTX trades at $33.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas TGTX's P/E ratio is 12.18. In terms of profitability, NSRX's ROE is +0.00%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, NSRX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check TGTX's competition here
NSRX vs FBIOX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, FBIOX has a market cap of 5.3B. Regarding current trading prices, NSRX is priced at $2.20, while FBIOX trades at $24.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas FBIOX's P/E ratio is N/A. In terms of profitability, NSRX's ROE is +0.00%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, NSRX is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check FBIOX's competition here
NSRX vs ERAS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ERAS has a market cap of 5.3B. Regarding current trading prices, NSRX is priced at $2.20, while ERAS trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ERAS's P/E ratio is -38.66. In terms of profitability, NSRX's ROE is +0.00%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, NSRX is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ERAS's competition here
NSRX vs APLS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, APLS has a market cap of 5.2B. Regarding current trading prices, NSRX is priced at $2.20, while APLS trades at $40.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas APLS's P/E ratio is 226.61. In terms of profitability, NSRX's ROE is +0.00%, compared to APLS's ROE of +0.08%. Regarding short-term risk, NSRX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check APLS's competition here
NSRX vs CAI Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CAI has a market cap of 5.1B. Regarding current trading prices, NSRX is priced at $2.20, while CAI trades at $18.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CAI's P/E ratio is -5.70. In terms of profitability, NSRX's ROE is +0.00%, compared to CAI's ROE of +0.25%. Regarding short-term risk, NSRX is less volatile compared to CAI. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check CAI's competition here
NSRX vs IMVT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, IMVT has a market cap of 5B. Regarding current trading prices, NSRX is priced at $2.20, while IMVT trades at $24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas IMVT's P/E ratio is -9.28. In terms of profitability, NSRX's ROE is +0.00%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, NSRX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check IMVT's competition here
NSRX vs CRSP Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, NSRX is priced at $2.20, while CRSP trades at $51.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CRSP's P/E ratio is -7.92. In terms of profitability, NSRX's ROE is +0.00%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, NSRX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CRSP's competition here
NSRX vs APGE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, APGE has a market cap of 4.8B. Regarding current trading prices, NSRX is priced at $2.20, while APGE trades at $86.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas APGE's P/E ratio is -20.44. In terms of profitability, NSRX's ROE is +0.00%, compared to APGE's ROE of -0.37%. Regarding short-term risk, NSRX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check APGE's competition here
NSRX vs MIRM Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, NSRX is priced at $2.20, while MIRM trades at $95.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas MIRM's P/E ratio is -202.55. In terms of profitability, NSRX's ROE is +0.00%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, NSRX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check MIRM's competition here
NSRX vs TERN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, TERN has a market cap of 4.7B. Regarding current trading prices, NSRX is priced at $2.20, while TERN trades at $52.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas TERN's P/E ratio is -51.10. In terms of profitability, NSRX's ROE is +0.00%, compared to TERN's ROE of -0.20%. Regarding short-term risk, NSRX is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check TERN's competition here
NSRX vs XENE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, XENE has a market cap of 4.6B. Regarding current trading prices, NSRX is priced at $2.20, while XENE trades at $58.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas XENE's P/E ratio is -13.15. In terms of profitability, NSRX's ROE is +0.00%, compared to XENE's ROE of -0.56%. Regarding short-term risk, NSRX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check XENE's competition here
NSRX vs FOLD Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, NSRX is priced at $2.20, while FOLD trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas FOLD's P/E ratio is -160.67. In terms of profitability, NSRX's ROE is +0.00%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, NSRX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check FOLD's competition here
NSRX vs AKRO Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, NSRX is priced at $2.20, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas AKRO's P/E ratio is -14.57. In terms of profitability, NSRX's ROE is +0.00%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, NSRX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check AKRO's competition here
NSRX vs CORT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CORT has a market cap of 4.5B. Regarding current trading prices, NSRX is priced at $2.20, while CORT trades at $41.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CORT's P/E ratio is 51.11. In terms of profitability, NSRX's ROE is +0.00%, compared to CORT's ROE of +0.15%. Regarding short-term risk, NSRX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CORT's competition here
NSRX vs ALPN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, NSRX is priced at $2.20, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ALPN's P/E ratio is -101.52. In terms of profitability, NSRX's ROE is +0.00%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, NSRX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ALPN's competition here
NSRX vs OPT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, NSRX is priced at $2.20, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas OPT's P/E ratio is -1.52. In terms of profitability, NSRX's ROE is +0.00%, compared to OPT's ROE of +0.88%. Regarding short-term risk, NSRX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check OPT's competition here
NSRX vs CRNX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CRNX has a market cap of 4.1B. Regarding current trading prices, NSRX is priced at $2.20, while CRNX trades at $39.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CRNX's P/E ratio is -8.03. In terms of profitability, NSRX's ROE is +0.00%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, NSRX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CRNX's competition here
NSRX vs MRTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, NSRX is priced at $2.20, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas MRTX's P/E ratio is -4.82. In terms of profitability, NSRX's ROE is +0.00%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, NSRX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check MRTX's competition here
NSRX vs LGND Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, NSRX is priced at $2.20, while LGND trades at $204.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas LGND's P/E ratio is 33.43. In terms of profitability, NSRX's ROE is +0.00%, compared to LGND's ROE of +0.14%. Regarding short-term risk, NSRX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check LGND's competition here
NSRX vs NAMS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, NAMS has a market cap of 4B. Regarding current trading prices, NSRX is priced at $2.20, while NAMS trades at $34.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas NAMS's P/E ratio is -20.21. In terms of profitability, NSRX's ROE is +0.00%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, NSRX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check NAMS's competition here
NSRX vs VKTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, NSRX is priced at $2.20, while VKTX trades at $34.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas VKTX's P/E ratio is -10.74. In terms of profitability, NSRX's ROE is +0.00%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, NSRX is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check VKTX's competition here
NSRX vs RYZB Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, NSRX is priced at $2.20, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas RYZB's P/E ratio is -57.86. In terms of profitability, NSRX's ROE is +0.00%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, NSRX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check RYZB's competition here
NSRX vs CBAY Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, NSRX is priced at $2.20, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CBAY's P/E ratio is -32.81. In terms of profitability, NSRX's ROE is +0.00%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, NSRX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CBAY's competition here
NSRX vs ACAD Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, NSRX is priced at $2.20, while ACAD trades at $21.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ACAD's P/E ratio is 9.45. In terms of profitability, NSRX's ROE is +0.00%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, NSRX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ACAD's competition here
NSRX vs TLX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, NSRX is priced at $2.20, while TLX trades at $10.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas TLX's P/E ratio is -527.00. In terms of profitability, NSRX's ROE is +0.00%, compared to TLX's ROE of -0.02%. Regarding short-term risk, NSRX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check TLX's competition here
NSRX vs SWTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, NSRX is priced at $2.20, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas SWTX's P/E ratio is -13.78. In terms of profitability, NSRX's ROE is +0.00%, compared to SWTX's ROE of -0.36%. Regarding short-term risk, NSRX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check SWTX's competition here
NSRX vs EWTX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, EWTX has a market cap of 3.5B. Regarding current trading prices, NSRX is priced at $2.20, while EWTX trades at $32.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas EWTX's P/E ratio is -20.13. In terms of profitability, NSRX's ROE is +0.00%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, NSRX is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check EWTX's competition here
NSRX vs KNSA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, NSRX is priced at $2.20, while KNSA trades at $47.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas KNSA's P/E ratio is 62.77. In terms of profitability, NSRX's ROE is +0.00%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, NSRX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check KNSA's competition here
NSRX vs DNTH Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, DNTH has a market cap of 3.4B. Regarding current trading prices, NSRX is priced at $2.20, while DNTH trades at $89.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas DNTH's P/E ratio is -21.37. In terms of profitability, NSRX's ROE is +0.00%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, NSRX is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check DNTH's competition here
NSRX vs LQDA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, LQDA has a market cap of 3.4B. Regarding current trading prices, NSRX is priced at $2.20, while LQDA trades at $38.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas LQDA's P/E ratio is -48.19. In terms of profitability, NSRX's ROE is +0.00%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, NSRX is less volatile compared to LQDA. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check LQDA's competition here
NSRX vs LEGN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, NSRX is priced at $2.20, while LEGN trades at $18.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas LEGN's P/E ratio is -11.21. In terms of profitability, NSRX's ROE is +0.00%, compared to LEGN's ROE of -0.29%. Regarding short-term risk, NSRX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check LEGN's competition here
NSRX vs VERA Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, VERA has a market cap of 3.2B. Regarding current trading prices, NSRX is priced at $2.20, while VERA trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas VERA's P/E ratio is -9.67. In terms of profitability, NSRX's ROE is +0.00%, compared to VERA's ROE of -0.60%. Regarding short-term risk, NSRX is less volatile compared to VERA. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check VERA's competition here
NSRX vs GPCR Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, GPCR has a market cap of 3.1B. Regarding current trading prices, NSRX is priced at $2.20, while GPCR trades at $54.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas GPCR's P/E ratio is -22.71. In terms of profitability, NSRX's ROE is +0.00%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, NSRX is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check GPCR's competition here
NSRX vs SYRE Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, SYRE has a market cap of 3.1B. Regarding current trading prices, NSRX is priced at $2.20, while SYRE trades at $51.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas SYRE's P/E ratio is -25.90. In terms of profitability, NSRX's ROE is +0.00%, compared to SYRE's ROE of -0.29%. Regarding short-term risk, NSRX is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check SYRE's competition here
NSRX vs TARS Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, TARS has a market cap of 3.1B. Regarding current trading prices, NSRX is priced at $2.20, while TARS trades at $72.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas TARS's P/E ratio is -45.64. In terms of profitability, NSRX's ROE is +0.00%, compared to TARS's ROE of -0.20%. Regarding short-term risk, NSRX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check TARS's competition here
NSRX vs DYN Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, DYN has a market cap of 3.1B. Regarding current trading prices, NSRX is priced at $2.20, while DYN trades at $18.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas DYN's P/E ratio is -5.38. In terms of profitability, NSRX's ROE is +0.00%, compared to DYN's ROE of -0.61%. Regarding short-term risk, NSRX is less volatile compared to DYN. This indicates potentially lower risk in terms of short-term price fluctuations for NSRX.Check DYN's competition here
NSRX vs CPRX Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, NSRX is priced at $2.20, while CPRX trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas CPRX's P/E ratio is 14.85. In terms of profitability, NSRX's ROE is +0.00%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, NSRX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check CPRX's competition here
NSRX vs DNLI Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, DNLI has a market cap of 3B. Regarding current trading prices, NSRX is priced at $2.20, while DNLI trades at $19.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas DNLI's P/E ratio is -6.47. In terms of profitability, NSRX's ROE is +0.00%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, NSRX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check DNLI's competition here
NSRX vs ARQT Comparison April 2026
NSRX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NSRX stands at 19M. In comparison, ARQT has a market cap of 3B. Regarding current trading prices, NSRX is priced at $2.20, while ARQT trades at $24.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NSRX currently has a P/E ratio of -3.11, whereas ARQT's P/E ratio is -186.23. In terms of profitability, NSRX's ROE is +0.00%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, NSRX is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for NSRX.Check ARQT's competition here